Drug
Brivanib alaninate
Brivanib alaninate is a pharmaceutical drug with 5 clinical trials. Historical success rate of 80.0%.
Total Trials
5
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
80.0%
Based on 4 completed trials
Completion Rate
80%(4/5)
Active Trials
0(0%)
Results Posted
75%(3 trials)
Terminated
1(20%)
Phase Distribution
Ph phase_3
1
20%
Ph phase_2
3
60%
Ph phase_1
1
20%
Phase Distribution
1
Early Stage
3
Mid Stage
1
Late Stage
Phase Distribution5 total trials
Phase 1Safety & dosage
1(20.0%)
Phase 2Efficacy & side effects
3(60.0%)
Phase 3Large-scale testing
1(20.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
80.0%
4 of 5 finished
Non-Completion Rate
20.0%
1 ended early
Currently Active
0
trials recruiting
Total Trials
5
all time
Status Distribution
Completed(4)
Terminated(1)
Detailed Status
Completed4
Terminated1
Development Timeline
Analytics
Development Status
Total Trials
5
Active
0
Success Rate
80.0%
Most Advanced
Phase 3
Trials by Phase
Phase 11 (20.0%)
Phase 23 (60.0%)
Phase 31 (20.0%)
Trials by Status
completed480%
terminated120%
Recent Activity
0 active trials
Showing 5 of 5
completedphase_3
Cetuximab With or Without Brivanib in Treating Patients With K-Ras Wild Type Tumours and Metastatic Colorectal Cancer
NCT00640471
terminatedphase_2
Brivanib Metastatic Renal Cell Carcinoma
NCT01253668
completedphase_2
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
NCT01267253
completedphase_2
Brivanib Alaninate in Treating Patients With Recurrent or Persistent Endometrial Cancer
NCT00888173
completedphase_1
Ascending Multiple-Dose Study of Brivanib Alaninate in Combination With Chemotherapeutic Agents in Subjects With Advanced Cancers
NCT00798252
Clinical Trials (5)
Showing 5 of 5 trials
NCT00640471Phase 3
Cetuximab With or Without Brivanib in Treating Patients With K-Ras Wild Type Tumours and Metastatic Colorectal Cancer
NCT01253668Phase 2
Brivanib Metastatic Renal Cell Carcinoma
NCT01267253Phase 2
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
NCT00888173Phase 2
Brivanib Alaninate in Treating Patients With Recurrent or Persistent Endometrial Cancer
NCT00798252Phase 1
Ascending Multiple-Dose Study of Brivanib Alaninate in Combination With Chemotherapeutic Agents in Subjects With Advanced Cancers
All 5 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 5